PATEL, D. et al. Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in Treatment of Patients With Polycystic Ovary Syndrome: A Systemic Review of Metabolic and Cardiovascular Outcomes. Journal For International Medical Graduates, v. 3, n. 1, 19 Feb.2024.